Actively Recruiting
Randomized Study of Intrathecal ALN-HTT02 for Safety and Pharmacodynamics in Adults with Huntingtons Disease
Led by Alnylam Pharmaceuticals · Updated on 2026-10-15
66
Participants Needed
19
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, pharmacodynamics, and pharmacokinetics of single or repeat doses of ALN-HTT02 in adults with stage 2 or early stage 3 Huntingtons Disease. This Phase 1 randomized, double-blind, placebo-controlled study focuses on understanding how ALN-HTT02 behaves and is tolerated when administered intrathecally to this patient population. Participants are randomly assigned to receive either a single dose of ALN-HTT02 or a placebo during the double-blind part of the study. Those who receive ALN-HTT02 will not get an additional dose in the open-label part, while placebo recipients have the option to receive a single dose of ALN-HTT02 later. An open-label extension offers participants the chance to receive repeat doses of ALN-HTT02 over a longer period. During the study, participants will be monitored for adverse events for up to 12 months in the double-blind and open-label parts, and up to 36 months in the extension. Researchers will measure levels of mutant huntingtin protein in cerebrospinal fluid and concentrations of ALN-HTT02 in plasma, cerebrospinal fluid, and urine. Safety and tolerability data will be collected throughout the study duration, which runs until 2028, with various clinical evaluations and sample collections at scheduled intervals.
CONDITIONS
Brief Title
A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease
Research Team
A
Alnylam Clinical Trial Information Line
A
Alnylam Clinical Trial Information Line
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here